No Detail Found!

Hypercoagulability andits CardiovascularImplications in COVID-19 Patients

Author(s)
Asim Iqbal N/A
Abstract
COVID-19, a viral respiratory illness caused by the severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2), is a new comer to the infectious disease list. First documented in Wuhan china and since then it has rapidly spread around the globe. Perhaps the most devastating pandemic of the modern era, it was first considered to be primarilya respiratory illness. But it is now an established fact that it can affect other body systems as well and may predispose patients to thrombotic complications, both in the venous and arterial circulations. This virus is still new and continuous research is being done in order to fully understand its pathophysiology and different factors that are related to increased mortality. Many patients already receiving antithrombotic therapy may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy.The objective of this article is to address the current understanding of the pathogenesis and management of patients with COVID-19 who need prevention from thrombotic disease, patients who develop thrombotic cardiovascular complications, patients with pre-existing thromboticdisease who develop COVID-19 and patients with COVID-19 who developed DIC.
Publication Details
Page(s) 170-174
DOI DOI not available
Published Journal: Journal of Cardiovascular Diseases, Volume: 16, Issue: 4, Year: 2020

Request the full text from PASTIC

Keywords
COVID-19 patients, Hypercoagulability
0

Citations

0

Downloads

38

Views